Roche announces $550 million investment to expand its Indianapolis diagnostics manufacturing hub
INDIANAPOLIS, May 12, 2025 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today it plans to invest up to $550 million in its Diagnostics site in Indianapolis by 2030. The site will become a major hub for the manufacturing of Roche's continuous glucose monitoring (CGM) systems – marking a new milestone in Roche's long history of revolutionizing healthcare across the globe.
Indianapolis serves as the North American headquarters for Roche Diagnostics, part of the Roche Group – the world's largest biotech company. This latest expansion underscores Roche's commitment to advancing science, driving innovation, and delivering cutting-edge solutions that improve patient outcomes.
With more than 38 million Americans living with diabetes,¹ access to effective disease management solutions is crucial. To address this growing need, Roche is investing in a new CGM manufacturing facility in Indianapolis. CGM technologies offer essential support for daily diabetes management, and this investment will help advance Roche's mission to improve patient care through innovation.
'The challenges of diabetes are pervasive, with millions of Americans living with the constant vigilance and countless daily decisions the disease requires,' said Brad Moore, President and CEO of Roche Diagnostics North America. 'By expanding our manufacturing capabilities in Indianapolis, we ensure reliable access to innovative monitoring solutions for individuals living with diabetes in the U.S. and worldwide.'
The Indianapolis campus houses key operations, including U.S. research and development, laboratories, manufacturing, distribution, IT and administrative functions. It currently produces approximately 5.2 billion Accu-Chek® diabetes test strips annually and serves as one of two global distribution hubs focused on serving the U.S. market and supporting distribution to 53 countries worldwide.
Building on more than $800 million in U.S. investments made at Roche U.S. sites since 2015, this new commitment reinforces Roche's longterm dedication to U.S. operations and highlights the country's central role in the company's global strategy.
The expansion is expected to generate hundreds of highly-skilled manufacturing jobs and thousands of construction jobs, providing a significant boost to Indiana's economy. It will also enhance domestic production capabilities and reduce dependency on imports – aligning with national efforts to strengthen local manufacturing.
About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalized healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
For over 125 years, sustainability has been an integral part of Roche's business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
References
1. American Diabetes Association, Statistics About Diabetes. Accessed March 26, 2025.
For Further Information
Roche Diagnostics U.S. Media Relations
[email protected]
Jen Dial
1-463-867-0232
[email protected]
View original content to download multimedia: https://www.prnewswire.com/news-releases/roche-announces-550-million-investment-to-expand-its-indianapolis-diagnostics-manufacturing-hub-302452305.html
SOURCE Roche Diagnostics
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Why AST SpaceMobile Stock Is Skyrocketing This Week
Jeff Bezos visited Space Mobile's Texas headquarters. A picture from the visit on social media fueled speculation that AST's relationship with Bezos' companies could grow. A public spat between Elon Musk and President Donald Trump could leave the door open for other space companies to win some of SpaceX's contracts. 10 stocks we like better than AST SpaceMobile › Shares of AST SpaceMobile (NASDAQ: ASTS) are moving higher this week, up 33.9% as of 2 p.m. ET from last Friday's close. The gain comes as the S&P 500 gained 1.5% and the Nasdaq-100 gained 2.2%. Earlier in the week, a board member posted a picture to social media that fueled speculation of a possible partnership with Jeff Bezos' Blue Origin. The stock also received a boost after yesterday's public spat between President Donald Trump and Elon Musk. After Bezos visited the company's Texas headquarters, AST board member Adriana Cisneros posted a picture of Bezos, AST CEO Abel Avellan, and herself to Instagram with the caption, "Amazing things are happening at AST & Science + Blue Origin." This fueled speculation that Blue Origin, Bezos' space exploration company, could be looking to create a closer relationship with AST. The company already has a contract with AST to launch 45 satellites, but a more formal partnership would be a game changer for AST SpaceMobile. Elon Musk and President Donald Trump escalated a public spat yesterday. What began when Musk took to X to criticize Trump's flagship "Big, Beautiful Bill" quickly turned personal and included Trump threatening to cancel contracts with Musk's SpaceX. If this were to happen, it could leave the door open for AST SpaceMobile to, at least partially, fill the void. This is all speculation; nothing is concrete. That being said, both of these possibilities represent a huge upside for AST. For investors with a high risk appetite, AST can be a solid pick. However, be aware that there is a significant risk. The company has a long way to go to justify its valuation. Before you buy stock in AST SpaceMobile, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and AST SpaceMobile wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $674,395!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $858,011!* Now, it's worth noting Stock Advisor's total average return is 997% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Johnny Rice has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why AST SpaceMobile Stock Is Skyrocketing This Week was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 minutes ago
- Yahoo
Obama's doctor says Biden's physician should have given him cognitive tests
Former President Joe Biden's doctor should have given him more cognitive tests, according to the doctor of former President Barack Obama. Jeffrey Kuhlman, who served as Obama's doctor between 2009 and 2013, told the New York Post on Saturday that Biden and any politician over the age of 70 should be given "a few hours" of annual mental exams that should be accessible to the public. 'My position is that a 78-year-old candidate, Trump at the time, an 82-year-old president [Biden] would both benefit from neurocognitive testing,' Kuhlman said. He went on to say that "any politician over the age of 70 has normal age-related cognitive decline," and pointed out that he's been recommending annual mental exams for more than a year. Biden's doctor, Kevin O'Connor, oversaw three physicals for the president during his time in office, but Kuhlman says the physical reports did not include notes from a neurocognitive specialist. He also pointed out that Biden did not take the Montreal Cognitive Assessment, which Donald Trump agreed to take during his first term. That test is a two-minute screening test of about 30 questions that probes for signs of dementia, according to Kuhlman. Obama's doctor said that he had "no doubts" that Trump "aced" the Montreal Cognitive Assessment, but said he believes that the White House should also release the CT scans taken after Trump's attempted assassination last year. While the Montreal test is able to detect some basic signs of dementia, the doctor noted that it wasn't adequate for determining more serious cognitive issues. According to Kuhlman, mental processing speed and spacial visualization all begin to decline around the age of 60. Kuhlman said he respected O'Connor's medical judgement, but added that "sometimes those closest to the trees miss the forest." O'Connor told the New York Post in July 2024 — just days after the then-president announced he would not run for re-election — that Biden's cognitive health was "excellent." Then-White House Press Secretary Karine Jean-Pierre insisted to the public that Biden didn't "need a cognitive test" because he "passes a cognitive test every day." She has since decided to leave the Democratic Party and write a tell-all book about her time in the White House, earning her a savaging by some Democrats. Visitor logs to the White House show that Biden did submit an evaluation form to an expert in Parkinson's Disease, but O'Connor said that the meeting was part of Biden's annual physical. Kuhlman says that the doctor who evaluated Biden in that visit, Kevin Cannard, had been evaluating Biden for 14 years, and that he trusts the doctor's evaluation. O'Connor was subpoenaed by the Republican-led House Oversight Committee on Thursday to stand for questioning about Biden's mental abilities during a hearing on June 27. Shortly after the House investigation was launched, the Trump administration issued a memo stating that it was issuing its own investigation into whether or not people other than Biden used an autopen signature device to sign off on executive actions during the late period of Biden's presidential term. Both investigations follow the release of a book by Jake Tapper and Alex Thompson, titled Original Sin, that alleges a mass coverup of Biden's cognitive impairment by those closest to him.
Yahoo
23 minutes ago
- Yahoo
NAVER Expands Startup Investments in Silicon Valley with the Planned Establishment of NAVER Ventures
- Key executives, including Founder Lee Hae-jin and CEO Choi Soo-yeon, engage in discussions with the local startup ecosystem- The new investment initiative will focus on investing in promising startups in North America, starting with video AI startup 'TwelveLabs'- NAVER has a strong track record of tech startup investments through its NAVER D2SF and is also known for acquiring Poshmark SEONGNAM, South Korea, June 7, 2025 /PRNewswire/ -- NAVER Corporation (CEO Choi Soo-yeon) announced the planned establishment of "NAVER Ventures," its new global venture investment initiative in Silicon Valley. The launch marks a significant step in NAVER's strategy to expand its global footprint and foster innovation by investing in promising startups in North America. NAVER Ventures aims to build on NAVER's experience in supporting startups through its NAVER D2SF, which has invested numerous early-stage technology startups and supported their overseas expansion. The company also expanded its global portfolio by acquiring Poshmark, a leading U.S.-based social commerce platform, in 2023. As part of its commitment to the Silicon Valley ecosystem, NAVER Founder and Chairman Lee Hae-jin, CEO Choi Soo-yeon, and Kim Namsun, President of investments visited the region to engage directly with entrepreneurs, engineers, and investors. They hosted the "Venturing NAVER's Next Chapter" networking event on June 5 at the Four Seasons Hotel, where they discussed NAVER's vision for supporting startups and fostering technological innovation. NAVER Ventures has confirmed its first investment in TwelveLabs, a video AI startup recognized for its innovative technology. The investment aligns with NAVER's focus on AI competitiveness and its strategy to collaborate with global startups to drive future growth. The new investment initiative, NAVER Ventures, overseen by Kim Namsun, is expected to complete its establishment process later this month. It will invest capital and expertise to help category-leading companies accelerate the growth of their businesses (/END) About NAVER Founded in 1999, NAVER is South Korea's largest Internet company and one of the world's leading technology companies. NAVER has grown into a global ICT company that leads in cutting-edge technologies and operates a diverse portfolio of businesses, including commerce, fintech, content, cloud services, AI, and robotics, as well as other global online services such as LINE mobile messenger, Webtoon and Webnovel publishing, SNOW video camera app and ZEPETO metaverse platform. NAVER is expanding its global footprint through strategic partnerships with industry leaders such as SoftBank, Poshmark, and Wattpad. Currently, TEAM NAVER strengthens business portfolios and expands its service regions, including Japan, North America, and Europe. In 2024, NAVER reported sales of KRW 10.74 trillion (approximately USD 7.5 billion) and NAVER is ranked as the 12th largest company in terms of market capitalization in Korea. To learn more, visit View original content to download multimedia: SOURCE NAVER Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
